Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dithranol + mometasone
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
A combination therapy used for treating psoriasis. Dithranol (anthralin) is an anthracene derivative that works by interfering with mitochondrial function, reducing DNA replication and keratinocyte proliferation, preventing T-cell activation, and restoring cell differentiation. Mometasone is a synthetic glucocorticoid that works by preventing inflammation. When used together (mometasone in the morning, dithranol in the evening), this combination has shown significantly faster reduction of psoriasis symptoms compared to dithranol monotherapy or calcipotriol/dithranol combination in the first week of treatment.
- Other names
- anthralin + mometasonedithranol + mometasone furoate
02
Targets
GR (Glucocorticoid receptor)NeuraminidaseCD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on dithranol + mometasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dithranol + mometasone.